Fluxid Approval History beta

Fluxid (famotidine orally disintegrating tablets) is a histamine H2-receptor antagonist indicated for the treatment of ulcers, gastroesophageal reflux disease and pathological hypersecretory conditions.

FDA Approval History for Fluxid

DateArticle
Sep 24, 2004Approval Fluxid Schwarz Pharma, Inc. - Treatment for Ulcers and other Gastrointestinal Conditions

See also...

Fluxid (famotidine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Trouble with Ulcerative Colitis? Learn about treatments to alleviate symptoms. Click Here

Close
(web5)